Coastline Trust Co Sells 2,450 Shares of Sanofi (NASDAQ:SNY)

Coastline Trust Co decreased its stake in shares of Sanofi (NASDAQ:SNYFree Report) by 20.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 9,320 shares of the company’s stock after selling 2,450 shares during the period. Coastline Trust Co’s holdings in Sanofi were worth $463,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in SNY. Sage Rhino Capital LLC boosted its holdings in Sanofi by 2.8% during the third quarter. Sage Rhino Capital LLC now owns 8,722 shares of the company’s stock valued at $468,000 after acquiring an additional 240 shares during the period. Gallacher Capital Management LLC boosted its stake in Sanofi by 4.5% during the 3rd quarter. Gallacher Capital Management LLC now owns 5,715 shares of the company’s stock valued at $307,000 after purchasing an additional 245 shares during the period. Captrust Financial Advisors grew its holdings in Sanofi by 0.9% in the 3rd quarter. Captrust Financial Advisors now owns 26,191 shares of the company’s stock valued at $996,000 after buying an additional 246 shares during the last quarter. Rise Advisors LLC increased its position in Sanofi by 98.4% in the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after buying an additional 251 shares during the period. Finally, Pathstone Family Office LLC lifted its holdings in shares of Sanofi by 1.7% during the fourth quarter. Pathstone Family Office LLC now owns 14,962 shares of the company’s stock worth $705,000 after buying an additional 251 shares during the last quarter. 10.04% of the stock is owned by institutional investors.

Sanofi Price Performance

Shares of Sanofi stock opened at $47.70 on Wednesday. The firm has a market cap of $120.66 billion, a P/E ratio of 20.21, a price-to-earnings-growth ratio of 1.79 and a beta of 0.61. The firm’s 50-day simple moving average is $47.98 and its 200-day simple moving average is $49.21. Sanofi has a twelve month low of $42.63 and a twelve month high of $57.82. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27.

Sanofi (NASDAQ:SNYGet Free Report) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a return on equity of 27.47% and a net margin of 12.56%. The business had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $13.02 billion. As a group, research analysts expect that Sanofi will post 4.19 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be given a $1.478 dividend. This represents a yield of 2.98%. This is a boost from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio is 58.47%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Morgan Stanley began coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective for the company. TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Finally, JPMorgan Chase & Co. cut Sanofi from an “overweight” rating to a “neutral” rating in a report on Tuesday, December 5th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $55.00.

Read Our Latest Stock Report on SNY

Sanofi Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Read More

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.